Verseon Playing The Long Game To Level Up Drug Discovery
Executive Summary
Adityo Prakash, CEO and founder of Verseon, tells In Vivo more about his vision of re-routing the pharmaceutical industry with Verseon’s computational drug discovery technology. He also explains the company’s new subsidiary business, BlockRules, and how it fits into the biopharma world.
You may also be interested in...
Snapshot: August Highlights
A selection of articles you might have missed from August 2020, including exclusive interviews with industry leaders and a review of financing trends.
‘Translators’ Will Form The Next Generation Of Biopharma Leaders
Rabia Khan, managing director of discovery sciences at Sensyne Health, talks to In Vivo about pairing biology with technology in the most effective way, managing COVID-19 challenges and what the future leaders of biopharma might look like.
How Has COVID-19 Influenced Investment Trends?
Health care funding in the first half of 2020 reached $10.4bn, according to a mid-year report from Silicon Valley Bank, nearly matching 2019’s full-year record. As well as the COVID-19 pandemic though, other global events, such as the US election, could become distractions in the second half of the year.
Need a specific report? 1000+ reports available Buy Reports